Transactions
1
Insider / TEVA PHARMACEUTICAL INDUSTRIES LTD
Lippman Evan
EVP, Business Development at TEVA PHARMACEUTICAL INDUSTRIES LTD
- Ticker
- TEVA
- First filing on record
- August 19, 2026
- Latest trade on record
- August 17, 2026
- SEC filings
- EDGAR ↗
Lippman Evan, EVP, Business Development at TEVA PHARMACEUTICAL INDUSTRIES LTD, has disclosed 1 transaction in TEVA since August 19, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $680K at the reported prices. The latest was filed August 19, 2026, 2 days after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months Lippman Evan made no purchases and 1 sale worth $680K. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Lippman Evan has traded 1 stock on record; the largest by dollars is TEVA.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 1 | 18,600 | $680K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 1 · $680K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | Sell S | August 17, 2026 | August 19, 2026 | 2d | 18,600 | $37 | $680K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 19, 2026 | Form 4 | 0001193125-26-356853 | 1 | published | EDGAR ↗ |
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD
- Savage Brian Interim Chief Legal Officer 5 rows
- Weiss Amir Chief Accounting Officer 4 rows
- Hughes Eric A See "Remarks" 3 rows
- Jover Placid See "Remarks" 3 rows
- MIGNONE ROBERTO Director 3 rows
- Kalif Eliyahu Sharon EVP, Chief Financial Officer 1 row
- Satchi-Fainaro Ronit Director 1 row
- Shields Matthew EVP, Global Operations 1 row
- Zaks Tal Zvi Director 1 row
Everyone on file, with contracts and lobbying under the company's name: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | August 19, 2026 | August 19, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.